197 related articles for article (PubMed ID: 30965052)
21. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
van de Vrie R; van Meurs HS; Rutten MJ; Naaktgeboren CA; Opmeer BC; Gaarenstroom KN; van Gorp T; Ter Brugge HG; Hofhuis W; Schreuder HWR; Arts HJG; Zusterzeel PLM; Pijnenborg JMA; van Haaften M; Engelen MJA; Boss EA; Vos MC; Gerestein KG; Schutter EMJ; Kenter GG; Bossuyt PMM; Mol BW; Buist MR
Gynecol Oncol; 2017 Sep; 146(3):449-456. PubMed ID: 28645428
[TBL] [Abstract][Full Text] [Related]
23. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
24. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470
[TBL] [Abstract][Full Text] [Related]
25. Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market.
Shih YT; Xu Y; Zhao H; Schrag D; Yao J
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34350376
[TBL] [Abstract][Full Text] [Related]
26. Can we maximize both value and quality in gynecologic cancer care? A work in progress.
Havrilesky LJ; Fountain C
Am Soc Clin Oncol Educ Book; 2014; ():e268-75. PubMed ID: 24857112
[TBL] [Abstract][Full Text] [Related]
27. Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States.
Zhao J; Zheng Z; Han X; Davidoff AJ; Banegas MP; Rai A; Jemal A; Yabroff KR
Value Health; 2019 Jul; 22(7):762-767. PubMed ID: 31277821
[TBL] [Abstract][Full Text] [Related]
28. Out-of-Pocket Costs for Advanced Imaging Across the US Private Insurance Marketplace.
Rosenkrantz AB; Sadigh G; Carlos RC; Silva E; Duszak R
J Am Coll Radiol; 2018 Apr; 15(4):607-614.e1. PubMed ID: 29477290
[TBL] [Abstract][Full Text] [Related]
29. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
Drews F; Bertelli G; Lutchman-Singh K
Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
[TBL] [Abstract][Full Text] [Related]
30. Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis.
Raborn ML; Pelletier EM; Smith DB; Reyes CM
Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP57-64. PubMed ID: 22693982
[TBL] [Abstract][Full Text] [Related]
31. Impact of Deductible Health Plans on Parental Decision Making for Common Pediatric Otolaryngology Procedures.
Sjogren PP; Hall D; Padia R; Stoddard GJ; Meier JD
Otolaryngol Head Neck Surg; 2018 Oct; 159(4):761-765. PubMed ID: 30084300
[TBL] [Abstract][Full Text] [Related]
32. Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
Lu CY; Zhang F; Wagner AK; Nekhlyudov L; Earle CC; Callahan M; LeCates R; Xu X; Ross-Degnan D; Wharam JF
Breast Cancer Res Treat; 2018 Aug; 171(1):235-242. PubMed ID: 29754304
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults.
Nabi J; Friedlander DF; Chen X; Cole AP; Hu JC; Kibel AS; Dasgupta P; Trinh QD
JAMA Netw Open; 2020 Jan; 3(1):e1919185. PubMed ID: 31940036
[TBL] [Abstract][Full Text] [Related]
34. Deductible double jeopardy: patients may pay more out of pocket when pregnancy crosses 2 years.
Duffy EL; Randall S; Green S; Trish E
Am J Manag Care; 2024 Jun; 30(6):285-288. PubMed ID: 38912954
[TBL] [Abstract][Full Text] [Related]
35. Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment.
Wharam JF; Zhang F; Lu CY; Wagner AK; Nekhlyudov L; Earle CC; Soumerai SB; Ross-Degnan D
J Clin Oncol; 2018 Apr; 36(11):1121-1127. PubMed ID: 29489428
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy with bevacizumab (i.p.) can prolong survival time of patients with advanced ovarian cancer after cytoreduction.
DU F; Li P; Chen J; Gong Z; Chi C; Hu B; Chu H
Neoplasma; 2017; 64(1):108-113. PubMed ID: 27881011
[TBL] [Abstract][Full Text] [Related]
37. Non-dialysis dependent chronic kidney disease is associated with high total and out-of-pocket healthcare expenditures.
Small C; Kramer HJ; Griffin KA; Vellanki K; Leehey DJ; Bansal VK; Markossian TW
BMC Nephrol; 2017 Jan; 18(1):3. PubMed ID: 28056852
[TBL] [Abstract][Full Text] [Related]
38. Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy.
Lee JY; Kim K; Lee YS; Kim HY; Nam EJ; Kim S; Kim SW; Kim JW; Kim YT
Gynecol Oncol; 2016 Dec; 143(3):622-627. PubMed ID: 27771167
[TBL] [Abstract][Full Text] [Related]
39. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer.
Suidan RS; He W; Sun CC; Zhao H; Ramondetta LM; Badgwell BD; Bodurka DC; Lu KH; Giordano SH; Meyer LA
Int J Gynecol Cancer; 2017 Sep; 27(7):1350-1359. PubMed ID: 28574929
[TBL] [Abstract][Full Text] [Related]
40. ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.
Foote J; Secord AA; Liang M; Cohn DE; Jewell E; Havrilesky LJ
J Oncol Pract; 2017 Dec; 13(12):e1030-e1039. PubMed ID: 29016225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
